^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | trastuzumab envedotin (DP303c) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
Published date:
09/17/2022
Excerpt:
In vitro and in vivo, DP303c showed stronger antitumor activity as compared to trastuzumab-DM1 (T-DM1) in a series of HER2-positive cancer cells and cell-derived xenograft (CDX) models, especially in the lower HER2-expressing cells….DP303c demonstrated remarkable anticancer efficacy against T-DM1 in xenograft models (having a high and low expression of HER2, accordingly), as well as a favorable PK and safety profile, implying that it has the potential to serve as a candidate drug in patients suffering from HER2 positive cancer.
